Roche (RHHBY) announced results from two clinical trials evaluating astegolimab in people with moderate to very severe chronic obstructive pulmonary disease or COPD, alongside standard maintenance therapy.
The pivotal Phase IIb ALIENTO trial met its primary endpoint, showing a statistically significant 15.4% reduction in annualized exacerbation rate (AER) at 52 weeks, with dosing every two weeks.
In contrast, the Phase III ARNASA trial did not meet its primary endpoint, recording a numerical AER reduction of 14.5% at 52 weeks, which did not reach statistical significance.
The company noted that results across secondary endpoints were generally consistent in both studies. The overall number of exacerbations was lower than anticipated. Astegolimab's safety profile aligned with previously reported data, with no new safety signals identified.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.